Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7459648 | 0.86 | GAA (0.38) | GAAEPHX2 | |
| SCHEMBL18229954 | 0.77 | KCNN4 (0.42) | KCNN4KCNA3CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL27743631 | 0.77 | MAPT (0.37) | KCNN4KCNA3ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL21233040 | 0.77 | KDM4E (0.39) | GAAKCNN4KCNA3ALDH1A1CYP11B1 | |
| SCHEMBL8313319 | 0.77 | KCNN4 (0.36) | KCNN4KCNA3CYP11B1CYP11B2 | |
| SCHEMBL69872 | 0.77 | KCNN4 (0.36) | KCNN4KCNA3CYP11B1CYP11B2 | |
| SCHEMBL511015 | 0.77 | ALDH1A1 (0.38) | KCNN4KCNA3ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL70574 | 0.77 | L3MBTL1 (0.44) | KCNN4KCNA3ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL369213 | 0.77 | CA4 (0.39) | GAAKCNN4KCNA3CYP11B1CYP11B2 | |
| SCHEMBL3152998 | 0.77 | TSHR (0.39) | GAAKCNN4KCNA3ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486276-B2 | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | PYRAMID BIOSCIENCES, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| US-20240246976-A1 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | PYRAMID BIOSCIENCES INC (US) | 2024-07-25 | — | — | US | disclosed |
| CN-117580824-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4237413-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-111819179-B | Related compounds as TRK kinase inhibitors for the treatment of cancer | 金字塔生物科技公司 | 2023-09-01 | — | — | CN | disclosed |
| US-11739096-B2 | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | PYRAMID BIOSCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230124248-A1 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | PYRAMID BIOSCIENCES, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20220235055-A1 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | PYRAMID BIOSCIENCES, INC. | 2022-07-28 | — | — | US | disclosed |
| EP-3724191-B9 | 5-(2-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | PYRAMID BIOSCIENCES INC (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3724191-A1 | 5-(2-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1 -YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | Pyramid Biosciences, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118584-A1 | 5-(2-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1 -YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | PYRAMID BIOSCIENCES, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-6617347-B1 | Substituted pyrazoles are treatment of Type II diabetes and obesity. | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| EP-1036064-A4 | SELECTIVE BETA 3-ADRENERGIC AGONISTS | LILLY CO ELI (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6232337-B1 | USEFUL IN THE TREATMENT OF TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY | 2001-05-15 | — | — | US | disclosed |
| EP-1036064-A1 | SELECTIVE BETA 3-ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2000-09-20 | — | — | EP | disclosed |
| US-6046227-A | USEFUL IN THE TREATMENT OF TYPE II DIABETES AND OBESITY; A SUBSTITUTED PYRAZINE COMPOUND | ELI LILLY AND COMPANY (US) | 2000-04-04 | — | — | US | disclosed |
| WO-1999029672-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
| WO-1999029673-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
| EP-0921120-A1 | Selective beta 3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1999-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739096-B2 | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | DTYMK, DCK, MAP3K9 | GAA 4560/4885EPHX2 4213/4885KCNN4 4412/4885 |
| US-20230124248-A1 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | DCK, DTYMK, MAP3K19 | GAA 4290/4885EPHX2 4120/4885KCNN4 4549/4885 |
| US-20220235055-A1 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | TPX2, FRK, PDXK | GAA 3563/4885EPHX2 4448/4885KCNN4 4317/4885 |
| US-12486276-B2 | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | DTYMK, DCK, MAP3K9 | GAA 4560/4885EPHX2 4213/4885KCNN4 4412/4885 |
| US-20240246976-A1 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | DTYMK, DCK, MAP3K9 | GAA 4560/4885EPHX2 4213/4885KCNN4 4412/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | GAA 1937/4885EPHX2 3368/4885KCNN4 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.